Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
By Dr. Matthew Watson
VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 2, 2025.
Read more from the original source:
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
Related Post
- Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - June 3rd, 2025
- Abivax Presents First Quarter 2025 Financial Results - June 3rd, 2025
- Cronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer Conference - June 3rd, 2025
- Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative... - June 3rd, 2025
- Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - June 3rd, 2025
- Vaxart Announces Adjournment of Annual Meeting of Stockholders - June 3rd, 2025
- Sernova Appoints Jonathan Rigby as Interim Chair - June 3rd, 2025
- Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes - June 3rd, 2025
- Harvard Bioscience Appoints John Duke to Board of Directors - June 3rd, 2025
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 3rd, 2025
- Quest PharmaTech Provides Corporate Update - June 3rd, 2025
- Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - June 3rd, 2025
- Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - June 3rd, 2025
- Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report - June 3rd, 2025
- Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - June 3rd, 2025
- argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference - June 3rd, 2025
- Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease - June 3rd, 2025
- Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer - June 3rd, 2025
- Addex Convenes Annual General Meeting 2025 - June 3rd, 2025
- Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 - May 26th, 2025
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - May 26th, 2025
- IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of... - May 26th, 2025
- Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 - May 26th, 2025
- Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting - May 26th, 2025
- Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - May 26th, 2025
- CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer - May 26th, 2025
- MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd. - May 26th, 2025
- Boundless Bio Announces Portfolio Prioritization and Runway Extension - May 26th, 2025
- Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year;... - May 26th, 2025
- AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - May 26th, 2025
- PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - May 26th, 2025
- Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - May 26th, 2025
- Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F - May 26th, 2025
- IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - May 26th, 2025
- Polyrizon Announces Receipt of Nasdaq Delisting Notice - May 26th, 2025
- Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant... - May 26th, 2025
- ZLNA – Issuance of shares through set-off of option exercise fee - May 26th, 2025
- Guerbet : Changes in the composition of the Guerbet board of directors. - May 26th, 2025
- Chair of Sernova Biotherapeutics Resigns - May 26th, 2025
- Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting - May 18th, 2025
- Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - May 18th, 2025
- Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day - May 18th, 2025
- Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates - May 18th, 2025
- Vivex Biologics, Inc. Executive Chair Nominated for Ernst & Young LLP Entrepreneur of the Year® 2025 Florida Award - May 18th, 2025
- PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025 - May 18th, 2025
- Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - May 18th, 2025
- Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform - May 18th, 2025
- Conduit Pharmaceuticals Inc. Announces Reverse Stock Split - May 18th, 2025
- BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement - May 18th, 2025
- Transactions of Managers and Closely Associated Persons - May 18th, 2025
- GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - May 18th, 2025
- Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the... - May 18th, 2025
- TestoPrime Reviews Side Effects (INVESTIGATED) Is This Testosterone Booster Safe? (Ingredients, Results & Where to Buy) - May 18th, 2025
- BlueSphere Bio Appoints Alan Korman, Ph.D. as Chief Scientific Officer - May 18th, 2025
- 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition - May 18th, 2025
- Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm - May 18th, 2025
- Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - May 18th, 2025
- Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the... - May 18th, 2025
- Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF... - May 18th, 2025
- Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - May 6th, 2025
- ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - May 6th, 2025
- uniQure to Announce First Quarter 2025 Financial Results - May 6th, 2025
- Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights - May 6th, 2025
- Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 - May 6th, 2025
- FibroGen to Report First Quarter 2025 Financial Results - May 6th, 2025
- Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates - May 6th, 2025
- Context Therapeutics Announces Chief Medical Officer Transition - May 6th, 2025
- Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates - May 6th, 2025
- Certara Reports First Quarter 2025 Financial Results - May 6th, 2025
- Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - May 6th, 2025
- DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - May 6th, 2025
- Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET - May 6th, 2025
- Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of... - May 6th, 2025
- Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company - May 6th, 2025
- Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with... - May 6th, 2025
- argenx to Present at BofA Securities 2025 Health Care Conference - May 6th, 2025
- Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity - May 6th, 2025
- Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy - May 6th, 2025
- Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation - May 6th, 2025
- Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa - April 23rd, 2025
Global News Feed
Comments Off on Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders |
June 3rd, 2025
This author published 6252 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research